

BC Cancer ST Program Updates for May 2023

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer VC/Vancouver General Hospital (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- For PowerPlans that are versioned: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop up window will appear to indicate a new version is required.
 - Click **Yes** to accept the new version.
 - **Do not** use the Copy Forward functionality to ensure that the updates apply.



- **IMPORTANT**: Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below:

PowerPlan: GIFUC

Cycles/PowerPlans: Associated Treatment Plan

Changes:

Chemotherapy Phase:

- Updated days of treatment to Day 1, Day 8, Day 15, Day 22.
- Added "Max Dose: 5000mg/48 hours" in order comments for fluorouracil.

ONCP GI GIFUC - Cycle 1, Chemotherapy (Day 1, 8, 15, 22) (Future Pending) *Est. 15-Apr-2023 08:00 PDT - 28 Days				
	Day 1	Day 8	Day 15	Day 22
Component	Future Pending	Future Pending	Future Pending	Future Pending
	*Est. 15-Apr-2023 08:...	*Est. 22-Apr-2023 08:...	*Est. 29-Apr-2023 08:...	*Est. 06-May-2023 08:...
	Actions ▾	Actions ▾	Actions ▾	Actions ▾
Target fluorouracil daily dose = 1000 mg/m2/day for 2 d...				
fluorouracil (fluorouracil - oncology) 2,000 mg/m2, IV, once oncology, administer over: 48 hour Max Dose: 5000mg/48 hours. In D5W to a total volume of 240...	+30 min Planned	+30 min Planned	+30 min Planned	+30 min Planned

Lab Phase:

- Updated days of treatment to Day 8, Day 15, Day 22, Day 29.

ONCP GI GIFUC - Cycle 1, Labs (Day 8, 15, 22, 29) (Future Pending) *Est. 20-Apr-2023 08:00 PDT - 29 Days				
	Day 8	Day 15	Day 22	Day 29
Component	Future Pending	Future Pending	Future Pending	Future Pending
	*Est. 20-Apr-2023 08:...	*Est. 27-Apr-2023 08:...	*Est. 04-May-2023 08:...	*Est. 11-May-2023 08:...
	Actions ▾	Actions ▾	Actions ▾	Actions ▾

Versioning: Yes

Jira: CST-211362

PowerPlan: ULYROMI

Cycles/PowerPlans: Pretreatment and Regimen

Changes:

Added note to Pretreatment Plan under CAP Note, in Regimen description and above list of PowerPlans.

- **No new patients effective 20 March 2023. Physicians must enroll existing patients via ISTODAX (romidepsin) Restricted Access Program (https://istodaxhprc.ptm-health.com/ENG.aspx?cid=R6370E&wave_no=1)**

ONCP LY ULYROMI Pretreatment Plan, Baseline Labs (Day 1) (Future Pending)

Component
A BC Cancer "Compassionate Access Program" (CAP) request form must be completed and approved prior to treatment
No new patients effective 20 March 2023. Physicians must enroll existing patients via ISTODAX (romidepsin) Restricted Access Program (https://istodaxhprc.ptm-health.com/ENG.aspx?cid=R6370E&wave_no=1)

ONCP LY ULYROMI (Pending)

▼ Hide additional details

Regimen description: Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with romidepsin

A BC Cancer "Compassionate Access Program" (CAP) request form must be completed and approved prior to treatment

No new patients effective 20 March 2023. Physicians must enroll existing patients via ISTODAX (romidepsin) Restricted Access Program (https://istodaxhprc.ptm-health.com/ENG.aspx?cid=R6370Ewave_no=1)

+ Add Document Response View Responses

A BC Cancer "Compassionate Access Program" (CAP) request form must be completed and approved prior to treatment

No new patients effective 20 March 2023. Physicians must enroll existing patients via ISTODAX (romidepsin) Restricted Access Program (https://istodaxhprc.ptm-health.com/ENG.aspx?cid=R6370Ewave_no=1)

Versioning: Yes

Jira: CST-211360

PowerPlan: UMYBLDF, UMYDARBD, UMYDARLD, UMYLDREL, UMYLENMTN, UMYCARDEX, UMYCARLD

Cycles/PowerPlans: All associated Treatment Regimens and PowerPlans

Changes:

These Regimens and PowerPlans are no longer CAP. U designation removed from all Regimens/PowerPlans and CAP note removed from all Regimens and pretreatment plans.

- ONC MY MYDARBD First Dose IV
- ONC MY MYDARBD First Dose IV Split Dosing
- ONC MY MYDARBD First Dose Subcutaneous
- ONCP MY MYDARBD Cycle 2
- ONCP MY MYDARBD Cycles 3 and 4
- ONCP MY MYDARBD Cycles 5 to 8
- ONCP MY MYDARBD Cycles 9+
- ONCP MY MYDARBD First Dose IV Cycle 1
- ONCP MY MYDARBD First Dose IV Split Dosing Cycle 1
- ONCP MY MYDARBD First Dose Subcutaneous Cycle 1
- ONCP MY MYDARBD Pretreatment Plan

ONC MY MYDARBD First Dose IV (Pending)

▼ Hide additional details

Regimen description: Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone With or Without Cyclophosphamide

+ Add Document Response View Responses

ONCP MY MYDARBD Pretreatment Plan

Start

Versioning: Yes

Jira: CST-211344

PowerPlan: LYRITZ

Cycles/PowerPlans: All associated PowerPlans and Regimens

Changes:

In the riTUXimab phase:

Updated Link to Protocol note to: Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for 90Y-Ibritumomab Tiuxetan (ZEVALIN®).

ONCP LY LYRITZ - Cycle 1, riTUXimab (Day 1, 7) (Future Pending) *Est. 14-

Component
Link to Protocol: Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for 90Y-Ibritumomab Tiuxetan (ZEVALIN®)

Scheduling Phase:

Updated reason for exam in the Infusion riTUXimab Chemotherapy Visit to: Coordinate administration of **90Y-Ibritumomab Tiuxetan (ZEVALIN®)** with Nuclear Medicine Department.

ONCP LY LYRITZ - Cycle 1, Scheduling (Initiated Pending)

Task	Details
<input checked="" type="checkbox"/> Infusion riTUXimab Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY, Chair Time: 335 minutes, Nurse Time: 60 minutes, ONCP LY LYRITZ - riTUXimab Day 1
<input checked="" type="checkbox"/> Infusion riTUXimab Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY, Coordinate administration of 90Y-Ibritumomab Tiuxetan (ZEVALIN®) with Nuclear Medicine Department Days 7, 8, or 9 - coordinate with Nuclear Medicine Department

Regimen:

Updated Regimen Description to: Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for 90Y-Ibritumomab Tiuxetan (ZEVALIN®).

ONC LY LYRITZ (Pending)

▼ Hide additional details

Regimen description: Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for 90Y-Ibritumomab Tiuxetan (ZEVALIN®)

Versioning: Yes

Jira: CST-211301

PowerPlan: SMAJPEM, SMAJPEM6

Cycles/PowerPlans: All associated PowerPlans and Regimens

Changes:

For SMAJPEM:

Update Regimen description and Link to Protocol note to: Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using Pembrolizumab.

ONC SM SMAJPEM (Pending)

▼ [Hide additional details](#)

Regimen description: Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using Pembrolizumab

For SMAJPEM6:

Update Regimen description and Link to Protocol note to: Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using 6-Weekly Pembrolizumab.

ONC SM SMAJPEM6 (Pending)

▼ [Hide additional details](#)

Regimen description: Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using 6-Weekly Pembrolizumab

Versioning: Yes

Jira: CST-211300

PowerPlan: GOCABR, GOCABRBEV

Cycles/PowerPlans: All associated Pretreatment Plans

Changes:

Removed mandatory Lactate Dehydrogenase from Baseline Labs phase:

ONCP GO GOCABR Pretreatment Plan, Baseline Labs (D)		
		Component
<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit
<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit
<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit
<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit
<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/> Cancer Antigen 125 Blood, once, Order for future visit
<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/> Cancer Antigen 15-3 Blood, once, Order for future visit
<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/> Cancer Antigen 19-9 Blood, once, Order for future visit
<input checked="" type="checkbox"/>		<input checked="" type="checkbox"/> Carcinoembryonic Antigen Blood, once, Order for future visit

Versioning: Yes

Jira: CST-211298

PowerPlan: GIAVPG
Cycles/PowerPlans: All associated PowerPlans
<p>Changes:</p> <p>In the Pretreatment Plan:</p> <ul style="list-style-type: none"> - Added an optional Carcinoembryonic Antigen, Gamma Glutamyl Transferase, INR, PTT.

ONCP GI GIAVPG Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est. 15-Apr-2023 08:

		Day 1
		Future Pending
		*Est. 15-Apr-2023 08:...
		Actions
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit	Planned
	<input checked="" type="checkbox"/> If clinically indicated:	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Cancer Antigen 19-9 Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Carcinoembryonic Antigen Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Gamma Glutamyl Transferase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> INR Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> PTT Blood, once, Order for future visit	

CISplatin and CARBOplatin Plans:

- Added an optional Carcinoembryonic Antigen, Gamma Glutamyl Transferase, INR, PTT.
- Updated CA 19-9 to only be on Day 21.

ONCP GI GIAVPG CARBOplatin Option - Cycle 1, Labs (Day 8, 21) (Future Pending) *Est. 21-Apr-2023 08:00 PDT - 21 Da

		Day 8	Day 21
		Future Pending	Future Pending
		*Est. 21-Apr-2023 08:...	*Est. 04-May-2023 08:...
		Actions	Actions
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit	Planned	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit	Planned	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit		Planned
	<input checked="" type="checkbox"/> If clinically indicated:		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Cancer Antigen 19-9 Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Carcinoembryonic Antigen Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Gamma Glutamyl Transferase Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> INR Blood, once, Order for future visit		
<input type="checkbox"/>	<input checked="" type="checkbox"/> PTT Blood, once, Order for future visit		

Versioning: Yes

Jira: CST-211297

PowerPlan: GIAVPANI

Cycles/PowerPlans: Associated PowerPlan

Changes:

In the Next Cycle Labs Phase:

- Added optional CBC and Differential, Creatinine Level, Bilirubin Total, Alanine Aminotransferase, Alkaline Phosphatase.

ONCP GI GIAVPANI - Cycle 1, Next Cycle Labs (Day 1) (Future Pending) *Est. 27-Apr-2023 08:00 F		
	Component	Day 1 Future Pending *Est. 27-Apr-2023 08:00 F Actions
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes Panel Outpati... Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Magnesium Level Blood, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Calcium Level Blood, once, Order for future visit	Planned
	<input checked="" type="checkbox"/> If clinically indicated:	
<input type="checkbox"/>	<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Carcinoembryonic Antigen Blood, once, Order for future visit	

Versioning: Yes

Jira: CST-211295






PowerPlan: LKAMLMIDO

Cycles/PowerPlans: ONCP LK LKAMLMIDO (PO) Induction and ONCP LK LKAMLMIDO (PO) Consolidation

Changes:

In the Diagnostics Phase:

- Special Instructions have been added to the Electrocardiogram 12 Lead orders to specify when the tests should be performed

		Component	Status	Dose ...	Details
ONCP LK LKAMLMIDO (PO) Consolidation - Cycle 1, Diagnostics (Future Pending)					
<input checked="" type="checkbox"/>		Electrocardiogram 12 Lead			Day 8
<input checked="" type="checkbox"/>		Electrocardiogram 12 Lead			Day 10
<input checked="" type="checkbox"/>		Electrocardiogram 12 Lead			Day 21

Versioning: Yes

Jira: CST-193452

Jira Ticket #	CST-211362, CST-211360, CST-211344, CST-211301, CST-211300, CST-211298, CST-211297, CST-211295, CST-193452
How-to questions?	http://cstcernerhelp.healthcarebc.ca/
Need further support?	CST Phone Support: 1-844-214-7444